← All trials
NCT05014581
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 30, 2021
- Primary completion
- Nov 30, 2023
- Completion date
- Dec 31, 2023
- First posted
- Aug 20, 2021
- Last posted
- Aug 20, 2021
- Enrollment
- 420
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Azienda Ospedaliera San Gerardo di MonzaLead sponsor
- Azienda Ospedaliera San Gerardo di MonzaReponsible party - principal investigator
- Galway University HospitalStudy chair
- San Gerardo HospitalOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.